Skip to main content

Raise History

Our science has attracted over $30 million from investors, public funds, grants, and incubator investments so far.

Investor Impact

Scimar’s operations are supported by our investors. Since launching our seed round in 2018, we’ve attracted over $13 million in private investments from more than 75 investors.

In mid-2021, we launched our Series A round to build infrastructure, accelerate our research and clinical trials, and support our subsequent market launches of SciMar NuPa Daily: a nutraceutical designed to protect hepatalin production.

Why Investors Choose Scimar

  • No other research group in the world is studying the hepatalin hormone discovered by Dr. W. Wayne Lautt. Hepatalin is at the centre of our discoveries.
  • Nearly half a billion people worldwide live with type 2 diabetes. Many millions more have prediabetes. Scimar’s product suite is poised to make a transformational difference in the prevention, diagnosis, and treatment of type 2 diabetes.
  • Our product pipeline is protected by patents.
  • Scimar’s research team is working toward producing a large enough physical sample of pure natural hepatalin to satisfy the terms of any material transfer agreement with a pharmaceutical company. We are less than a gram away.

Our Raise History *

A graph displays Scimar's raise history. The y-axis lists the "Value of SciMar's Technology in Millions." It ranges from zero dollars to 500 million dollars in Canadian currency. The x-axis lists calendar years, ranging from 1996 to 2022. The value of Scimar's technology steadily grows higher with each passing year.

Public funds, grants, and incubator investments (attracted by Dr. Lautt while working as an academic):$17.3 million
Seed round, 2018–2021:$9.5 million
Bridge round, 2021:$3.5 million in preferred convertible shares
Series A round, 2022:$3.7 million


*All funds expressed in Canadian dollars